$5.94
8.33% today
Nasdaq, Apr 03, 06:47 pm CET
ISIN
US92764N1028
Symbol
VIR

Vir Biotechnology Inc Stock price

$6.48
-1.44 18.18% 1M
-1.20 15.63% 6M
-0.86 11.72% YTD
-3.14 32.64% 1Y
-18.85 74.42% 3Y
-22.78 77.85% 5Y
+2.79 75.61% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.30 4.85%
ISIN
US92764N1028
Symbol
VIR
Sector
Industry

Key metrics

Market capitalization $888.69m
Enterprise Value $-8.15m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.02
EV/Sales (TTM) EV/Sales -0.11
P/S ratio (TTM) P/S ratio 11.98
P/B ratio (TTM) P/B ratio 0.77
Revenue growth (TTM) Revenue growth -13.90%
Revenue (TTM) Revenue $74.21m
EBIT (operating result TTM) EBIT $-523.37m
Free Cash Flow (TTM) Free Cash Flow $-453.65m
Cash position $994.73m
EPS (TTM) EPS $-3.83
P/E forward negative
P/S forward 32.42
EV/Sales forward negative
Short interest 9.35%
Show more

Is Vir Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Vir Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vir Biotechnology Inc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Vir Biotechnology Inc forecast:

Buy
78%
Hold
22%

Financial data from Vir Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
74 74
14% 14%
100%
- Direct Costs 15 15
46% 46%
21%
59 59
2% 2%
79%
- Selling and Administrative Expenses 104 104
27% 27%
141%
- Research and Development Expense 463 463
13% 13%
624%
-509 -509
17% 17%
-686%
- Depreciation and Amortization 15 15
43% 43%
20%
EBIT (Operating Income) EBIT -523 -523
18% 18%
-705%
Net Profit -522 -522
15% 15%
-703%

In millions USD.

Don't miss a Thing! We will send you all news about Vir Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vir Biotechnology Inc Stock News

Neutral
PRNewsWire
13 days ago
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ...
Neutral
Business Wire
21 days ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta (CHD). ECLIPSE 1, the first trial of the program to be ...
Neutral
Seeking Alpha
about one month ago
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therap...
More Vir Biotechnology Inc News

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Head office United States
CEO Marianne Backer
Employees 408
Founded 2016
Website www.vir.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today